Cognition Therapeutics (CGTX) Other Non-Current Liabilities (2020 - 2023)

Cognition Therapeutics (CGTX) has 3 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q2 2023.

• Quarterly Other Non-Current Liabilities fell 37.79% year-over-year to $1.1 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.1 million (down 37.79% YoY) and the FY2022 annual result came in at $1.7 million, changed N/A from the prior year.
• Other Non-Current Liabilities fell to $1.1 million in Q2 2023 per CGTX's latest filing, from $1.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.2 million in Q4 2020 and bottomed at $1.1 million in Q2 2023.
• The 3-year median for Other Non-Current Liabilities is $1.7 million (2022), against an average of $1.7 million.
• Peak annual rise in Other Non-Current Liabilities reached 5.42% in 2023, while the deepest fall reached 37.79% in 2023.
• Tracing CGTX's Other Non-Current Liabilities over 3 years: stood at $2.2 million in 2020, then dropped by 23.68% to $1.7 million in 2022, then slumped by 37.6% to $1.1 million in 2023.
• Per Business Quant, the three latest CGTX Other Non-Current Liabilities figures stand at $1.1 million (Q2 2023), $1.8 million (Q1 2023), and $1.7 million (Q4 2022).

Peer Comparison